Literature DB >> 21793762

Drug-induced effects on erlotinib metabolism.

Olivier Mir, Benoit Blanchet, François Goldwasser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21793762     DOI： 10.1056/NEJMc1105083

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  15 in total

Review 1.  The quest to overcome resistance to EGFR-targeted therapies in cancer.

Authors:  Curtis R Chong; Pasi A Jänne
Journal:  Nat Med       Date:  2013-11-07       Impact factor: 53.440

Review 2.  Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer.

Authors:  Adrian G Sacher; Pasi A Jänne; Geoffrey R Oxnard
Journal:  Cancer       Date:  2014-04-17       Impact factor: 6.860

3.  The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.

Authors:  Yoon Ki Cha; Ho Yun Lee; Myung-Ju Ahn; Keunchil Park; Jin Seok Ahn; Jong-Mu Sun; Yoon-La Choi; Kyung Soo Lee
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

Review 4.  Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation.

Authors:  Kevin Becker; Yiqing Xu
Journal:  World J Clin Oncol       Date:  2014-10-10

5.  Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old.

Authors:  Frederic Bigot; Pascaline Boudou-Rouquette; Jennifer Arrondeau; Audrey Thomas-Schoemann; Camille Tlemsani; Jeanne Chapron; Olivier Huillard; Anatole Cessot; Michel Vidal; Jerome Alexandre; Benoit Blanchet; Francois Goldwasser
Journal:  Invest New Drugs       Date:  2016-10-29       Impact factor: 3.850

6.  Molecular-targeted therapy for elderly patients with advanced non-small cell lung cancer.

Authors:  Giovanna Antonelli; Massimo Libra; Vincenzo Panebianco; Alessia Erika Russo; Felice Vito Vitale; Paolo Colina; Alessandro D'Angelo; Rosalba Rossello; Francesco Ferraù
Journal:  Oncol Lett       Date:  2015-11-10       Impact factor: 2.967

Review 7.  Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies.

Authors:  Christine M Lovly; Alice T Shaw
Journal:  Clin Cancer Res       Date:  2014-05-01       Impact factor: 12.531

8.  Prevalence of drug-drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management.

Authors:  Audrey Bellesoeur; Ithar Gataa; Pascaline Boudou-Rouquette; Audrey Thomas-Schoemann; Anne Jouinot; Sarah El Mershati; Anne-Catherine Piketty; Camille Tlemsani; David Balakirouchenane; Anthia Monribot; Michel Vidal; Rui Batista; Sixtine de Percin; Clémentine Villeminey; Jérôme Alexandre; François Goldwasser; Benoit Blanchet
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-24       Impact factor: 3.333

9.  Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer.

Authors:  Jasmine Foo; Juliann Chmielecki; William Pao; Franziska Michor
Journal:  J Thorac Oncol       Date:  2012-10       Impact factor: 15.609

Review 10.  Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.

Authors:  Kadoaki Ohashi; Yosef E Maruvka; Franziska Michor; William Pao
Journal:  J Clin Oncol       Date:  2013-02-11       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.